UMIN-CTR History

Name:  UMIN ID:


Unique ID issued by UMIN UMIN000005428
Receipt number R000005907
Scientific Title Phase 1/2 study of the combination of Bendamustine and Rituximab for treatment of relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Date of disclosure of the study information 2011/04/12
Last modified on 2020/04/19 17:21:01

No. Disposal Last modified on Item of update
1 Insert 2011/04/12 22:52:29
2 Update 2020/04/19 17:03:18 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
TEL
Email

Last name of contact person

Last name of contact person
Zip code
TEL
Email
Name of primary person or sponsor
Organization
Post marketing survey by drug manufacture etc., specified by Japanese law.
Organization
Organization
Address
Address
Tel
Email
3 Update 2020/04/19 17:06:34 Date of IRB
Last follow-up date
4 Update 2020/04/19 17:21:01 Last follow-up date